News | May 21, 2026
Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
The company reported free cash flow of Rs. 2,590 Mn for FY26
But acquisition charges drag earnings into loss
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Shantived Hospital generated revenue of around Rs 50 crore in FY2025
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Delivers robust earnings performance, successfully navigating a dynamic environment
Overall investment in the US facility is estimated around US$50 million
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Subscribe To Our Newsletter & Stay Updated
